Please use this link to access this publication. Abstract The global prevalence of cannabis use during pregnancy is increasing, driven by perceived therapeutic benefits and greater societal acceptance. Concurrently, the psychoactive potency of cannabis products has risen significantly, due to increase in concentrations of Tetrahydrocannabinol (THC) from 5% to 30%. THC crosses the placenta, disrupts the endocannabinoid system critical for neurodevelopment, and accumulates in fetal tissues. THC is transferred into breast milk, with breastfed infants receiving ~2.5% of the maternal dose, raising concerns regarding neurodevelopmental consequences. An increasing number of studies and metanalysis have demonstrated association of prenatal cannabis exposure with low birth weight,...